Novartis has recently released trial data showing that Cosentyx was shown to be significantly more effective in treating patients with psoriasis when compared to the Johnson & Johnson’s rival biologic Stelara. According to the published results from the head-to-head CLARITY study, 66.5% of patients treated with Cosentyx achieved the primary endpoint PASI 90 (a 90%
Now in its third year, the Academy was initiated to provide appropriately trained new candidates to fill the large quantity of entry level roles available within the life science industry and, in particular, the clinical research sector. Our First to Industry Training Academy is designed to identify, fully fund and train the most talented life
GSK presents new data showing that its asthma drug Nucala can significantly improve quality of life and lung function in patients with severe, eosinophilic form of asthma. The Phase IIIb MUSCA study had met all its primary and secondary endpoints successfully, showing that when the treatment was added to standard of care, patients experienced significant
Clinical Professionals Group CEO, Yvette Cleland, comments on the “growing plague” currently affecting the life science industry: Approximately a year and a half ago, Clinical Professionals launched their Life Sciences Academies, with the aim to fully fund, train and then support 12 months of CPD for some of the UK’s brightest life sciences graduates, many
Bristol-Myers Squibb Company and Nektar Therapeutics have announced a new clinical collaboration to evaluate combining Bristol-Myers Squibb’s Opdivo with Nektar’s investigational medicine, NKTR-214, as a potential treatment regimen in five different tumour types and seven potential indications. Opdivo is a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. Whilst NKTR-214 is an investigational immuno-stimulatory
Bayer and Evotec have recently signed a five-year, multi-target research pact with the aim to develop multiple clinical candidates for the treatment of chronic kidney diseases. Both parties will contribute novel drug targets and a comprehensive set of high-quality technology platforms to jointly develop new innovative treatment options for patients, and will share responsibilities during
Last month our CEO, Yvette Cleland, contributed her thoughts and opinions on the staff shortage crisis currently affecting the clinical research industry to a BioPharm Insight article: The CRO industry’s acute understaffing issue is likely to become more of a burden to sponsors and CROs as trial volumes increase while recruitment stagnates, said experts. While the
Clinical data gathered for Sandoz’s biosimilar Etanercept (derived from Amgen and Pfizer’s Enbrel) was based from a “landmark” trial design in psoriasis in which over 500 patients switched from the original drug to the biosimilar. The data from the EGALITY trial showed the Novartis unit’s biosimilar, filed in the US and EU, met primary endpoint
Cancer Research UK’s Centre for Drug Development (CDD), in partnership with Amgen, have launched a new clinical trial to test a drug with the aim to stop a patient’s immune system from protecting tumours.
Heptares has announced positive findings from its Phase 1b clinical study with its investigational drug HTL9936 as a treatment for patients with cognitive impairment due to dementia and schizophrenia. During the Phase 1b study, 28 healthy elderly subjects were given different doses of HTL9936, to test the effect of drug on measures of brain activity
